研究性水痘疫苗在12-15月龄幼儿中的免疫原性与安全性II期试验
这项II期观察者盲法随机多中心对照试验在12-15月龄幼儿中比较研究性水痘疫苗(VNS)低、中、高三个效力剂量与已上市对照疫苗的单剂免疫原性和安全性,共入组800人,765人完成研究。接种后43天各组抗VZV糖蛋白E抗体几何平均浓度总体相近,血清应答率93.6%至98.7%,不良事件和严重不良事件的发生率、严重程度及持续时间在各组间相似。
要点
- VNS低、中、高剂量组接种后43天抗VZV gE抗体GMC分别为960、1071、1555 mIU/ml,对照组为1284 mIU/ml。
- 血清应答率从VNS低剂量组93.6%到高剂量组98.7%,对照组为98.1%。
- 各组不良事件与严重不良事件的发生率、严重程度和持续时间相似。
核心结论
- 单剂VNS疫苗三个效力剂量均具有免疫原性且安全性可接受。
研究设计与样本
- II期观察者盲法随机多中心对照试验,入组12-15月龄幼儿800人,来自4国55个中心,765人(95.6%)完成研究。
主要发现
- 接种后43天抗VZV糖蛋白E抗体GMC在VNS低、中、高剂量组分别为960 mIU/ml(95%CI 843-1093)、1071 mIU/ml(95%CI 952-1204)、1555 mIU/ml(95%CI 1407-1718),对照组为1284 mIU/ml(95%CI 1136-1453)。
- 第43天血清应答率从VNS低剂量组93.6%至VNS高剂量组98.7%,对照组为98.1%。
- 不良事件和严重不良事件的发生率、严重程度及持续时间在所有研究组间相似。
关键数值与推荐
- 免疫原性于接种后43天评估,安全性数据收集至接种后181天。
- 所有参与者同时接种甲肝疫苗和麻腮风疫苗,并按国家建议同时接种肺炎球菌结合疫苗。
临床怎么用
- 提示单剂VNS疫苗在12-15月龄幼儿中可诱导与对照疫苗总体相近的抗体应答,且安全性可接受。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Varicella is an acute, highly contagious infectious disease that primarily impacts young children with approximately 90% of cases occurring under the age of 15. Due to the high incidence of varicella infection, the potential for serious complications, and the significant economic and public health burden, vaccination of toddlers against varicella is included in routine vaccination programs in many countries. This study assessed the immunogenicity and safety of the investigational varicella vaccine (VNS) compared to a licensed, current standard-of-care vaccine. In this phase II, observer-blind, randomized, multicenter, controlled study, toddlers (12 to 15 months of age) received a single dose of the VNS vaccine (low, medium or high potency), or a single dose of the control vaccine. Hepatitis A and measles-mumps-rubella vaccines were co-administered to all participants. Pneumococcal conjugate vaccine was co-administered to all study participants as per national recommendations. Immunogenicity was assessed 43 days after vaccination; safety data were collected for up to 181 days post-vaccination. Overall, 800 participants were enrolled from 55 study centers across four countries (Estonia, Poland, Taiwan, and the United States), of whom 765 (95.6%) completed the study. Anti-varicella zoster virus glycoprotein E antibody geometric mean concentrations were generally comparable across study groups (960 mIU/ml [95% confidence interval [CI]: 843-1093], 1071 mIU/ml [952-1204] and 1555 mIU/ml [1407-1718] in the VNS-Low, VNS-Med and VNS-High groups, versus 1284 mIU/ml [1136-1453] in the control group). Seroresponse rates at Day 43 ranged from 93.6% in the VNS-Low group to 98.7% in the VNS-High group and 98.1% in the control group. The rate of occurrence, severity, and duration of adverse events and serious adverse events were similar across all study groups. These results show that the VNS vaccine was immunogenic with an acceptable safety profile following a single dose of all three potencies. Clinical trial registration number:NCT05084508.
引用
- Habib MA, Domachowske JB, Senders S, et al. Immunogenicity and safety of an investigational varicella zoster vaccine in toddlers aged 12-15 months: results of a phase II, controlled, randomized trial. Vaccine. 2026. PMID: 41825190. doi:10.1016/j.vaccine.2026.128439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。